4月27日，据CDE官网消息，江苏威凯尔医药科技股份有限公司联合申请药品“VC005片”，获得临床试验默示许可，受理号CXHL2500200。
公示信息显示，药品“VC005片”适应症：非节段型白癜风。
江苏威凯尔医药科技股份有限公司，成立于2010年，位于南京市，是一家以从事医药制造业为主的企业。企业注册资本7024.1779万人民币，实缴资本6900万人民币。
通过天眼查大数据分析，江苏威凯尔医药科技股份有限公司共对外投资了3家企业，参与招投标项目19次，知识产权方面有商标信息12条，专利信息47条，此外企业还拥有行政许可74个。
主要股东信息显示，江苏威凯尔医药科技股份有限公司由南京威越华生物科技合伙企业（有限合伙）持股26.8596%、亚泰医药集团有限公司持股12.0806%、先进制造产业投资基金二期（有限合伙）持股11.6065%、江苏疌泉成达股权投资中心（有限合伙）持股9.7349%、姜锋持股3.7348%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.